Current approaches for predicting a lack of response to Anti-EGFR therapy in KRAS wild-type patients

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Er, Tze Kiong ^a   Chen, Chih Chieh ^a,b   Bujanda, Luis ^c   Herreros Villanueva, Marta ^c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; CANCER ANTIBODY; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; RAS PROTEIN;

ANTIBODY RESPONSE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER THERAPY; CLINICAL PRACTICE; COLORECTAL CANCER; CONTROLLED STUDY; GENE MUTATION; HUMAN; ONCOGENE N RAS; PROTEIN STRUCTURE; REVIEW; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM;

ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GTP PHOSPHOHYDROLASES; HUMANS; MEMBRANE PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84904110420     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/591867     Document Type: Review

References (70)

1. Siegel R., Desantis C., Virgo K., Stein K., Mariotto A., Smith T., Cooper D., Gansler T., Lerro C., Fedewa S., Lin C., Leach C., Cannady R. S., Cho H., Scoppa S., Hachey M., Kirch R., Jemal A., Ward E., Cancer treatment and survivorship statistics, 2012. CA: A Cancer Journal for Clinicians 2012 62 4 220 241 2-s2.0-84863707351 10.3322/caac.21149
2. Walther A., Johnstone E., Swanton C., Midgley R., Tomlinson I., Kerr D., Genetic prognostic and predictive markers in colorectal cancer. Nature Reviews Cancer 2009 9 7 489 499 2-s2.0-67649506174 10.1038/nrc2645
3. Sunada H., Magun B. E., Mendelsohn J., MacLeod C. L., Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proceedings of the National Academy of Sciences of the United States of America 1986 83 11 3825 3829 2-s2.0-0008486660 (Pubitemid 16062376)
4. Smith C. G., Fisher D., Claes B., Maughan T. S., Idziaszczyk S., Peuteman G., Harris R., James M. D., Meade A., Jasani B., Adams R. A., Kenny S., Kaplan R., Lambrechts D., Cheadle J. P., Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clinical Cancer Research 2013 19 15 4104 4113 2-s2.0-84881255039 10.1158/1078-0432.CCR-12-2581
5. Zhao L., Vogt P. K., Helical domain and kinase domain mutations in p110 α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proceedings of the National Academy of Sciences of the United States of America 2008 105 7 2652 2657 2-s2.0-40649096375 10.1073/pnas.0712169105 (Pubitemid 351520568)
6. Amado R. G., Wolf M., Peeters M., van Cutsem E., Siena S., Freeman D. J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S. D., Chang D. D., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008 26 10 1626 1634 2-s2.0-42649145667 10.1200/JCO.2007.14.7116
7. de Roock W., Piessevaux H., de Schutter J., Janssens M., de Hertogh G., Personeni N., Biesmans B., Van Laethem J.-L., Peeters M., Humblet Y., Van Cutsem E., Tejpar S., KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Annals of Oncology 2008 19 3 508 515 2-s2.0-40149088765 10.1093/annonc/mdm496 (Pubitemid 351325672)
8. di Fiore F., Blanchard F., Charbonnier F., Le Pessot F., Lamy A., Galais M. P., Bastit L., Killian A., Sesboüé R., Tuech J. J., Queuniet A. M., Paillot B., Sabourin J. C., Michot F., Michel P., Frebourg T., Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer 2007 96 8 1166 1169 2-s2.0-34247278727 10.1038/sj.bjc.6603685 (Pubitemid 46625066)
9. Lièvre A., Bachet J.-B., Boige V., Cayre A., Le Corre D., Buc E., Ychou M., Bouché O., Landi B., Louvet C., André T., Bibeau F., Diebold M.-D., Rougier P., Ducreux M., Tomasic G., Emile J.-F., Penault-Llorca F., Laurent-Puig P., KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. Journal of Clinical Oncology 2008 26 3 374 379 2-s2.0-38649099966 10.1200/JCO.2007.12.5906 (Pubitemid 351171687)
10. Herreros-Villanueva M., Rodrigo M., Claver M., Muñiz P., Lastra E., García-Girón C., Coma Del Corral M. J., KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Molecular Biology Reports 2011 38 2 1315 1320 2-s2.0-79951578834 10.1007/s11033-010-0232-x
11. Karapetis C. S., Khambata-Ford S., Jonker D. J., O'Callaghan C. J., Tu D., Tebbutt N. C., Simes R. J., Chalchal H., Shapiro J. D., Robitaille S., Price T. J., Shepherd L., Au H.-J., Langer C., Moore M. J., Zalcberg J. R., K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England Journal of Medicine 2008 359 17 1757 1765 2-s2.0-54949085398 10.1056/NEJMoa0804385
12. Diaz L. A. Jr., Williams R. T., Wu J., Kinde I., Hecht J. R., Berlin J., Allen B., Bozic I., Reiter J. G., Nowak M. A., Kinzler K. W., Oliner K. S., Vogelstein B., The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012 486 7404 537 540 2-s2.0-84863000299 10.1038/nature11219
13. Custodio A., Feliu J., Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Critical Reviews in Oncology/Hematology 2013 85 1 45 81 2-s2.0-84870812342 10.1016/j.critrevonc.2012.05.001
14. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K. W., Vogelstein B., Velculescu V. E., RAF/RAS oncogenes and mismatch-repair status. Nature 2002 418 6901 934 2-s2.0-0037194728 10.1038/418934a (Pubitemid 34976022)
15. Kolch W., Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochemical Journal 2000 351 2 289 305 2-s2.0-0034667593 10.1042/0264-6021:3510289
16. Roth A. D., Tejpar S., Delorenzi M., Yan P., Fiocca R., Klingbiel D., Dietrich D., Biesmans B., Bodoky G., Barone C., Aranda E., Nordlinger B., Cisar L., Labianca R., Cunningham D., Van Cutsem E., Bosman F., Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. Journal of Clinical Oncology 2010 28 3 466 474 2-s2.0-75749102647 10.1200/JCO.2009.23.3452
17. Minoo P., Moyer M. P., Jass J. R., Role of BRAF -V600E in the serrated pathway of colorectal tumourigenesis. Journal of Pathology 2007 212 2 124 133 2-s2.0-34249785078 10.1002/path.2160 (Pubitemid 46852090)
18. van Cutsem E., Köhne C.-H., Láng I., Folprecht G., Nowacki M. P., Cascinu S., Shchepotin I., Maurel J., Cunningham D., Tejpar S., Schlichting M., Zubel A., Celik I., Rougier P., Ciardiello F., Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology 2011 29 15 2011 2019 2-s2.0-79956298812 10.1200/JCO.2010.33.5091
19. van Cutsem E., Köhne C.-H., Hitre E., Zaluski J., Chien C.-R. C., Makhson A., D'Haens G., Pintér T., Lim R., Bodoky G., Roh J. K., Folprecht G., Ruff P., Stroh C., Tejpar S., Schlichting M., Nippgen J., Rougier P., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine 2009 360 14 1408 1417 2-s2.0-63849088630 10.1056/NEJMoa0805019
20. Bokemeyer C., Bondarenko I., Hartmann J. T., de Braud F., Schuch G., Zubel A., Celik I., Schlichting M., Koralewski P., Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Annals of Oncology 2011 22 7 1535 1546 2-s2.0-79956310674 10.1093/annonc/mdq632
21. Seymour M. T., Brown S. R., Middleton G., Maughan T., Richman S., Gwyther S., Lowe C., Seligmann J. F., Wadsley J., Maisey N., Chau I., Hill M., Dawson L., Falk S., O'Callaghan A., Benstead K., Chambers P., Oliver A., Marshall H., Napp V., Quirke P., Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. The Lancet Oncology 2013 14 8 749 759 2-s2.0-84879786289 10.1016/S1470-2045(13)70163-3
22. Loupakis F., Ruzzo A., Cremolini C., Vincenzi B., Salvatore L., Santini D., Masi G., Stasi I., Canestrari E., Rulli E., Floriani I., Bencardino K., Galluccio N., Catalano V., Tonini G., Magnani M., Fontanini G., Basolo F., Falcone A., Graziano F., KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. British Journal of Cancer 2009 101 4 715 721 2-s2.0-68749119351 10.1038/sj.bjc.6605177
23. Maughan T. S., Adams R. A., Smith C. G., Meade A. M., Seymour M. T., Wilson R. H., Idziaszczyk S., Harris R., Fisher D., Kenny S. L., Kay E., Mitchell J. K., Madi A., Jasani B., James M. D., Bridgewater J., Kennedy M. J., Claes B., Lambrechts D., Kaplan R., Cheadle J. P., Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. The Lancet 2011 377 9783 2103 2114 2-s2.0-79959337678 10.1016/S0140-6736(11)60613-2
24. de Roock W., Claes B., Bernasconi D., de Schutter J., Biesmans B., Fountzilas G., Kalogeras K. T., Kotoula V., Papamichael D., Laurent-Puig P., Penault-Llorca F., Rougier P., Vincenzi B., Santini D., Tonini G., Cappuzzo F., Frattini M., Molinari F., Saletti P., de Dosso S., Martini M., Bardelli A., Siena S., Sartore-Bianchi A., Tabernero J., Macarulla T., di Fiore F., Gangloff A. O., Ciardiello F., Pfeiffer P., Qvortrup C., Hansen T. P., Van Cutsem E., Piessevaux H., Lambrechts D., Delorenzi M., Tejpar S., Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. The Lancet Oncology 2010 11 8 753 762 2-s2.0-77955277111 10.1016/S1470-2045(10)70130-3
25. di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., de Dosso S., Mazzucchelli L., Frattini M., Siena S., Bardelli A., Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Journal of Clinical Oncology 2008 26 35 5705 5712 2-s2.0-57449095367 10.1200/JCO.2008.18.0786
26. Sagaert X., Prognostic biomarkers in colorectal cancer: where do we stand? Virchows Archiv 2014 464 3 379 391 10.1007/s00428-013-1532-z
27. Benvenuti S., Sartore-Bianchi A., di Nicolantonio F., Zanon C., Moroni M., Veronese S., Siena S., Bardelli A., Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Research 2007 67 6 2643 2648 2-s2.0-34047248571 10.1158/0008-5472.CAN-06-4158 (Pubitemid 46548951)
28. Herreros-Villanueva M., Gomez-Manero N., Muñiz P., García-Girón C., Coma del Corral M. J., PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population. Molecular Biology Reports 2011 38 2 1347 1351 2-s2.0-79951579573 10.1007/s11033-010-0236-6
29. Tol J., Koopman M., Cats A., Rodenburg C. J., Creemers G. J. M., Schrama J. G., Erdkamp F. L. G., Vos A. H., Van Groeningen C. J., Sinnige H. A. M., Richel D. J., Voest E. E., Dijkstra J. R., Vink-Börger M. E., Antonini N. F., Mol L., Van Krieken J. H. J. M., Dalesio O., Punt C. J. A., Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. The New England Journal of Medicine 2009 360 6 563 572 2-s2.0-59749091477
30. Bokemeyer C., Bondarenko I., Hartmann J. T., de Braud F., Schuch G., Zubel A., Celik I., Schlichting M., Koralewski P., Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Annals of Oncology 2011 22 7 1535 1546 2-s2.0-79956310674 10.1093/annonc/mdq632
31. Saridaki Z., Tzardi M., Sfakianaki M., BRAF V600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome. PLoS ONE 2013 8 10.1371/journal.pone.0084604 e84604
32. Downward J., Targeting RAS signalling pathways in cancer therapy. Nature Reviews Cancer 2003 3 1 11 22 2-s2.0-0037264633 10.1038/nrc969 (Pubitemid 37328883)
33. Wang Y., Velho S., Vakiani E., Peng S., Bass A. J., Chu G. C., Gierut J., Bugni J. M., Der C. J., Philips M., Solit D. B., Haigis K. M., Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression. Cancer Discovery 2013 3 3 294 307 2-s2.0-84876064070 10.1158/2159-8290.CD-12-0198
34. Shen Y., Wang J., Han X., Yang H., Wang S., Lin D., Shi Y., Effectors of epidermal growth factor receptor pathway: the genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS ONE 2013 8 12 10.1371/journal.pone.0081628 e81628
35. Russo A. L., Borger D. R., Szymonifka J., Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer 2014 120 10 1482 1490 10.1002/cncr.28599
36. di Bartolomeo M., Pietrantonio F., Perrone F., Dotti K. F., Lampis A., Bertan C., Beretta E., Rimassa L., Carbone C., Biondani P., Passalacqua R., Pilotti S., Bajetta E., Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. Targeted Oncology 2013 2-s2.0-84879493704 10.1007/s11523-013-0283-8
37. Douillard J. Y., Oliner K. S., Siena S., Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. The New England Journal of Medicine 2013 369 11 1023 1034 10.1056/NEJMoa1305275
38. Sclafani F., Gonzalez D., Cunningham D., RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. European Journal of Cancer 2014 50 8 1430 1436 10.1016/j.ejca.2014.02.002
39. Perrone F., Lampis A., Orsenigo M., di Bartolomeo M., Gevorgyan A., Losa M., Frattini M., Riva C., Andreola S., Bajetta E., Bertario L., Leo E., Pierotti M. A., Pilotti S., PI3KCA / PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Annals of Oncology 2009 20 1 84 90 2-s2.0-59049089201 10.1093/annonc/mdn541
40. Nosho K., Kawasaki T., Ohnishi M., Suemoto Y., Kirkner G. J., Zepf D., Yan L., Longtine J. A., Fuchs C. S., Ogino S., PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008 10 6 534 541 2-s2.0-44449133319 10.1593/neo.08336 (Pubitemid 351770297)
41. Prenen H., de Schutter J., Jacobs B., de Roock W., Biesmans B., Claes B., Lambrechts D., Van Cutsem E., Tejpar S., PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clinical Cancer Research 2009 15 9 3184 3188 2-s2.0-65649086786 10.1158/1078-0432.CCR-08-2961
42. de Roock W., Claes B., Bernasconi D., de Schutter J., Biesmans B., Fountzilas G., Kalogeras K. T., Kotoula V., Papamichael D., Laurent-Puig P., Penault-Llorca F., Rougier P., Vincenzi B., Santini D., Tonini G., Cappuzzo F., Frattini M., Molinari F., Saletti P., De Dosso S., Martini M., Bardelli A., Siena S., Sartore-Bianchi A., Tabernero J., Macarulla T., Di Fiore F., Gangloff A. O., Ciardiello F., Pfeiffer P., Qvortrup C., Hansen T. P., Van Cutsem E., Piessevaux H., Lambrechts D., Delorenzi M., Tejpar S., Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. The Lancet Oncology 2010 11 8 753 762 2-s2.0-77955277111 10.1016/S1470-2045(10)70130-3
43. Sartore-Bianchi A., Martini M., Molinari F., Veronese S., Nichelatti M., Artale S., Di Nicolantonio F., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S., Bardelli A., PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR -targeted monoclonal antibodies. Cancer Research 2009 69 5 1851 1857 2-s2.0-62449302407 10.1158/0008-5472.CAN-08- 2466
44. Karapetis C. S., Jonker D., Daneshmand M., PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer-results from NCIC CTG/AGITG CO.17. Clinical Cancer Research 2014 20 3 744 753 10.1158/1078-0432.CCR-13-0606
45. Yang Z.-Y., Wu X.-Y., Huang Y.-F., Di M.-Y., Zheng D.-Y., Chen J.-Z., Ding H., Mao C., Tang J.-L., Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. International Journal of Cancer 2013 133 8 1914 1925 2-s2.0-84881543270 10.1002/ijc.28153
46. Cully M., You H., Levine A. J., Mak T. W., Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nature Reviews Cancer 2006 6 3 184 192 2-s2.0-33644513730 10.1038/nrc1819 (Pubitemid 43292562)
47. di Cristofano A., Pandolfi P. P., The multiple roles of PTEN in tumor suppression. Cell 2000 100 4 387 390 2-s2.0-0034681264
48. Sartore-Bianchi A., di Nicolantonio F., Nichelatti M., Molinari F., de Dosso S., Saletti P., Martini M., Cipani T., Marrapese G., Mazzucchelli L., Lamba S., Veronese S., Frattini M., Bardelli A., Siena S., Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR -targeted monoclonal antibodies in colorectal cancer. PLoS ONE 2009 4 10 2-s2.0-70350028742 10.1371/journal.pone.0007287 e7287
49. Jhawer M., Goel S., Wilson A. J., PIK3CA mutation/ PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Research 2008 68 6 1953 1961 10.1158/0008-5472.CAN- 07-5659 (Pubitemid 351416582)
50. Frattini M., Saletti P., Romagnani E., Martin V., Molinari F., Ghisletta M., Camponovo A., Etienne L. L., Cavalli F., Mazzucchelli L., PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. British Journal of Cancer 2007 97 8 1139 1145 2-s2.0-35348908314 10.1038/sj.bjc.6604009 (Pubitemid 47587019)
51. Loupakis F., Pollina L., Stasi I., Ruzzo A., Scartozzi M., Santini D., Masi G., Graziano F., Cremolini C., Rulli E., Canestrari E., Funel N., Schiavon G., Petrini I., Magnani M., Tonini G., Campani D., Floriani I., Cascinu S., Falcone A., PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. Journal of Clinical Oncology 2009 27 16 2622 2629 2-s2.0-66849140563 10.1200/JCO.2008.20.2796
52. Razis E., Briasoulis E., Vrettou E., Skarlos D. V., Papamichael D., Kostopoulos I., Samantas E., Xanthakis I., Bobos M., Galanidi E., Bai M., Gikonti I., Koukouma A., Kafiri G., Papakostas P., Kalogeras K. T., Kosmidis P., Fountzilas G., Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC Cancer 2008 8, article 234 2-s2.0-51249089269 10.1186/1471-2407-8-234
53. Cappuzzo F., Magrini E., Ceresoli G. L., Bartolini S., Rossi E., Ludovini V., Gregorc V., Ligorio C., Cancellieri A., Damiani S., Spreafico A., Paties C. T., Lombardo L., Calandri C., Bellezza G., Tonato M., Crino L., Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. Journal of the National Cancer Institute 2004 96 15 1133 1141 2-s2.0-4444332925 (Pubitemid 39207049)
54. Scartozzi M., Giampieri R., Maccaroni E., Mandolesi A., Biagetti S., Alfonsi S., Giustini L., Loretelli C., Faloppi L., Bittoni A., Bianconi M., Del Prete M., Bearzi I., Cascinu S., Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. Journal of Translational Medicine 2012 10 1, article 71 2-s2.0-84862235601 10.1186/1479-5876-10-71
55. Wheeler D. L., Huang S., Kruser T. J., Nechrebecki M. M., Armstrong E. A., Benavente S., Gondi V., Hsu K.-T., Harari P. M., Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008 27 28 3944 3956 2-s2.0-46249087766 10.1038/onc.2008.19 (Pubitemid 351913636)
56. Bardelli A., Corso S., Bertotti A., Hobor S., Valtorta E., Siravegna G., Sartore-Bianchi A., Scala E., Cassingena A., Zecchin D., Apicella M., Migliardi G., Galimi F., Lauricella C., Zanon C., Perera T., Veronese S., Corti G., Amatu A., Gambacorta M., Diaz L. A. Jr., Sausen M., Velculescu V. E., Comoglio P., Trusolino L., di Nicolantonio F., Giordano S., Siena S., Amplification of the MET receptor drives resistance to anti- EGFR therapies in colorectal cancer. Cancer Discovery 2013 3 6 658 673 2-s2.0-84878862323 10.1158/2159-8290.CD-12- 0558
57. Martin V., Landi L., Molinari F., Fountzilas G., Geva R., Riva A., Saletti P., de Dosso S., Spitale A., Tejpar S., Kalogeras K. T., Mazzucchelli L., Frattini M., Cappuzzo F., HER2 gene copy number status may influence clinical efficacy to anti- EGFR monoclonal antibodies in metastatic colorectal cancer patients. British Journal of Cancer 2013 108 3 668 675 2-s2.0-84875217382 10.1038/bjc.2013.4
58. Rubinson D. A., Hochster H. S., Ryan D. P., Wolpin B. M., McCleary N. J., Abrams T. A., Chan J. A., Iqbal S., Lenz H. J., Lim D., Rose J., Bekaii-Saab T., Chen H. X., Fuchs C. S., Ng K., Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Investigational New Drugs 2014 32 1 113 122 2-s2.0-84875871030 10.1007/s10637-013-9956-5
59. Bartel D. P., MicroRNAs: target recognition and regulatory functions. Cell 2009 136 2 215 233 2-s2.0-58249088751 10.1016/j.cell.2009.01.002
60. Raisch J., Darfeuille-Michaud A., Nguyen H. T., Role of microRNAs in the immune system, inflammation and cancer. World Journal of Gastroenterology 2013 19 20 2985 2996 10.3748/wjg.v19.i20.2985
61. Cappuzzo F., Sacconi A., Landi L., MicroRNA signature in metastatic colorectal cancer patients treated with anti- EGFR monoclonal antibodies. Clinical Colorectal Cancer 2014 13 1 37 45.e4 10.1016/j.clcc.2013.11.006
62. Ragusa M., Majorana A., Statello L., Maugeri M., Salito L., Barbagallo D., Guglielmino M. R., Duro L. R., Angelica R., Caltabiano R., Biondi A., di Vita M., Privitera G., Scalia M., Cappellani A., Vasquez E., Lanzafame S., Basile F., di Pietro C., Purrello M., Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Molecular Cancer Therapeutics 2010 9 12 3396 3409 2-s2.0-78650505164 10.1158/1535-7163.MCT-10-0137
63. Ruzzo A., Graziano F., Vincenzi B., Canestrari E., Perrone G., Galluccio N., Catalano V., Loupakis F., Rabitti C., Santini D., Tonini G., Fiorentini G., Rossi D., Falcone A., Magnani M., High let-7a microRNA levels in KRAS -mutated colorectal carcinomas may rescue anti- EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. The Oncologist 2012 17 6 823 829 2-s2.0-84862877840 10.1634/theoncologist.2012-0081
64. Zhang W., Winder T., Ning Y., Pohl A., Yang D., Kahn M., Lurje G., LaBonte M. J., Wilson P. M., Gordon M. A., Hu-Lieskovan S., Mauro D. J., Langer C., Rowinsky E. K., Lenz H.-J., A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Annals of Oncology 2011 22 1 104 109 2-s2.0-78650321266 10.1093/annonc/mdq315
65. Sebio A., Paré L., Páez D., Salazar J., González A., Sala N., Del Río E., Martín-Richard M., Tobeña M., Barnadas A., Baiget M., The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: its role in the efficacy of anti- EGFR -based therapy in metastatic colorectal cancer patients. Pharmacogenetics and Genomics 2013 23 3 142 147 2-s2.0-84873412791 10.1097/FPC.0b013e32835d9b0b
66. Pichler M., Ress A. L., Winter E., MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients. British Journal of Cancer 2014 110 6 1614 1621 10.1038/bjc.2014.51
67. Pichler M., Winter E., Ress A. L., miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. Journal of Clinical Pathology 2013 67 3 198 203 10.1136/jclinpath-2013-201904
68. Aubin F., Gill S., Burkes R., Colwell B., Kamel-Reid S., Koski S., Pollett A., Samson B., Tehfe M., Wong R., Young S., Soulières D., Canadian expert group consensus recommendations: KRAS testing in colorectal cancer. Current Oncology 2011 18 4 e180 e184 2-s2.0-80051535563
69. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti- EGFR therapy? Genetics in Medicine 2013 15 7 517 527 2-s2.0-84880544985 10.1038/gim.2012.184
70. Therkildsen C., Bergmann T. K., Henrichsen-Schnack T., Ladelund S., Nilbert M., The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti- EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncologica 2014 10.3109/0284186X.2014.895036